Compare Adaptive Biotechnologies Corp (ADPT) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | GSG | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $34.77 |
52-Week Low | $12.30 | $22.06 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $32.62, up 0.93% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The ETF's performance is heavily tied to energy commodities, which drove strong gains in H1 2026, though recent analyst sentiment has turned cautious due to sector volatility. Key support is at $31, with resistance at $32.
The outlook for GSG hinges on commodity market dynamics, particularly energy prices, offering exposure to broad commodities but facing risks from geopolitical tensions and volatility. Investor caution is warranted as analysts highlight increased risks near current price levels, with a recent downgrade to Hold reflecting concerns over sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
